Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases

[1]  K. Sun,et al.  Role of the lncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC , 2017, Molecular Cancer.

[2]  R. Rajasekharan,et al.  Human alpha beta hydrolase domain containing protein 11 and its yeast homolog are lipid hydrolases. , 2017, Biochemical and biophysical research communications.

[3]  R. Savino,et al.  Targeted proteomic approach in prostatic tissue: a panel of potential biomarkers for cancer detection , 2016, Oncoscience.

[4]  Isabel R Schlaepfer,et al.  Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles Biogenesis , 2016, International journal of molecular sciences.

[5]  Pär Stattin,et al.  The Proteome of Primary Prostate Cancer. , 2016, European urology.

[6]  C. Peters,et al.  Impact of cathepsin B on the interstitial fluid proteome of murine breast cancers. , 2016, Biochimie.

[7]  G. Kristiansen,et al.  Konsenskonferenz 2014 der ISUP zur Gleason-Graduierung des Prostatakarzinoms , 2016, Der Pathologe.

[8]  S. Beloribi-Djefaflia,et al.  Lipid metabolic reprogramming in cancer cells , 2016, Oncogenesis.

[9]  U. Haberkorn,et al.  New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy , 2016, Clinical Cancer Research.

[10]  Richard Hodson.  Small organ, big reach , 2015, Nature.

[11]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[12]  H. Wiker,et al.  Improving genome annotation of enterotoxigenic Escherichia coli TW10598 by a label‐free quantitative MS/MS approach , 2015, Proteomics.

[13]  V. Filipovski,et al.  Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer , 2015, The Prostate.

[14]  Danny F. Martinez,et al.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer , 2015, Clinical Cancer Research.

[15]  Peter Hoffmann,et al.  Proteomic developments in the analysis of formalin-fixed tissue. , 2015, Biochimica et biophysica acta.

[16]  Kai Blin,et al.  antiSMASH 3.0—a comprehensive resource for the genome mining of biosynthetic gene clusters , 2015, Nucleic Acids Res..

[17]  Y. Qiu,et al.  Role of PARP-1 in prostate cancer. , 2015, American journal of clinical and experimental urology.

[18]  Sang J. Chung,et al.  A Lactate-Induced Response to Hypoxia , 2015, Cell.

[19]  V. Drendel,et al.  Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only , 2015, Strahlentherapie und Onkologie.

[20]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[21]  C. Horbinski,et al.  PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. , 2014, Carcinogenesis.

[22]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[23]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[24]  O. Schilling,et al.  Impact of routinely employed procedures for tissue processing on the proteomic analysis of formalin‐fixed paraffin‐embedded tissue , 2014, Proteomics. Clinical applications.

[25]  A. Chinnaiyan,et al.  Molecular Pathways Molecular Pathways : Targeting ETS Gene Fusions in Cancer , 2014 .

[26]  Marco Y. Hein,et al.  Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ * , 2014, Molecular & Cellular Proteomics.

[27]  K. Knudsen,et al.  Transcriptional Roles of PARP1 in Cancer , 2014, Molecular Cancer Research.

[28]  Ling Tang,et al.  Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy. , 2014, Histology and histopathology.

[29]  Jingsong Zhang.  Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer , 2014, Asian journal of andrology.

[30]  Andrew R. Jones,et al.  ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination , 2014, Nature Biotechnology.

[31]  N. Lumen,et al.  Prognostic factors influencing prostate cancer‐specific survival in non‐castrate patients with metastatic prostate cancer , 2014, The Prostate.

[32]  R. Platt,et al.  Targeted versus universal decolonization to prevent ICU infection. , 2013, The New England journal of medicine.

[33]  S. Reske,et al.  Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. , 2012, The Journal of urology.

[34]  A. Chinnaiyan,et al.  Dual roles of PARP-1 promote cancer growth and progression. , 2012, Cancer discovery.

[35]  Chun-mei Wang,et al.  miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. , 2011, Oncology reports.

[36]  R. Aebersold,et al.  Activity-based proteomics: identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. , 2011, Journal of proteomics.

[37]  M. Mann,et al.  Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry. , 2010, Journal of proteome research.

[38]  Runsheng Li,et al.  NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth , 2009, International journal of cancer.

[39]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[40]  T. Veenstra,et al.  Mass spectrometric analysis of formalin‐fixed paraffin‐embedded tissue: Unlocking the proteome within , 2006, Proteomics.

[41]  Brian L Hood,et al.  Proteomic Analysis of Formalin-fixed Prostate Cancer Tissue*S , 2005, Molecular & Cellular Proteomics.

[42]  C. Cooper,et al.  Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer , 2004, British Journal of Cancer.

[43]  J. Yates,et al.  A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.

[44]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[45]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  M. Mann,et al.  Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. , 2003, Analytical chemistry.

[47]  Steven Piantadosi,et al.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.

[48]  A. Bürkle.  PARP‐1: A Regulator of Genomic Stability Linked with Mammalian Longevity , 2001, Chembiochem : a European journal of chemical biology.

[49]  Roger E Bumgarner,et al.  Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. , 2001, Cancer research.

[50]  J. Isaacs,et al.  Prostate‐specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells , 2000, The Prostate.

[51]  B. Snel,et al.  STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. , 2000, Nucleic acids research.

[52]  I Vergote,et al.  A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. , 1997, Journal of clinical pathology.

[53]  J. Swinnen,et al.  Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. , 1996, Endocrinology.

[54]  F T Bosman,et al.  Quality control in immunocytochemistry: experiences with the oestrogen receptor assay. , 1992, Journal of clinical pathology.

[55]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[56]  F. A. Putt,et al.  Histopathologic Technic and Practical Histochemistry , 1954, The Yale Journal of Biology and Medicine.

[57]  M. Piccart,et al.  An update on PARP inhibitors—moving to the adjuvant setting , 2015, Nature Reviews Clinical Oncology.

[58]  I. Tannock,et al.  The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. , 2014, European urology.

[59]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[60]  Fuchu He,et al.  Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family , 2004, Molecular and Cellular Biochemistry.

[61]  B. Ponder,et al.  Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. , 2003, American journal of human genetics.

[62]  M. Sadelain,et al.  A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? , 2001, Critical reviews in immunology.